Results of a phase II trial for high-risk neuroblastoma treatment protocol JN-H-07: a report from the Japan Childhood Cancer Group Neuroblastoma Committee (JNBSG)-Reference-Cited by-同舟云学术

Results of a phase II trial for high-risk neuroblastoma treatment protocol JN-H-07: a report from the Japan Childhood Cancer Group Neuroblastoma Committee (JNBSG)

Published:2018-04-26 Issue:5 Volume:23 Page:965-973
ISSN:1341-9625
Container-title:International Journal of Clinical Oncology
language:en
Short-container-title:Int J Clin Oncol

Author:

Hishiki Tomoro, ,Matsumoto Kimikazu,Ohira Miki,Kamijo Takehiko,Shichino Hiroyuki,Kuroda Tatsuo,Yoneda Akihiro,Soejima Toshinori,Nakazawa Atsuko,Takimoto Tetsuya,Yokota Isao,Teramukai Satoshi,Takahashi Hideto,Fukushima Takashi,Kaneko Takashi,Hara Junichi,Kaneko Michio,Ikeda Hitoshi,Tajiri Tatsuro,Nakagawara Akira

Funder

Japan Agency for Medical Research and Development

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Hematology,General Medicine,Surgery

Link

http://link.springer.com/article/10.1007/s10147-018-1281-8/fulltext.html

Reference26 articles.

1. Bolande RP (1974) The neurocristopathies: a unifying concept of disease arising in neural crest maldevelopment. Hum Pathol 5:409–429

2. Kreissman SG, Seeger RC, Matthay KK et al (2013) Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial. Lancet Oncol 14:999–1008. https://doi.org/10.1016/S1470-2045(13)70309-7

3. Pearson AD, Pinkerton CR, Lewis IJ et al (2008) High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial. Lancet Oncol 9:247–256